Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

被引：6

作者：

Roussel, Murielle ^{[1
,2
]}

Hebraud, Benjamin ^{[1
,2
]}

Hulin, Cyrille ^{[3
]}

Leleu, Xavier ^{[4
]}

Facon, Thierry ^{[5
]}

Boyle, Eileen ^{[6
]}

Touzeau, Cyrille ^{[7
]}

Pegourie, Brigitte ^{[8
]}

Perrot, Aurore ^{[9
,10
]}

Stoppa, Anne-Marie ^{[11
]}

Marolleau, Jean-Pierre ^{[12
]}

Moreau, Philippe ^{[13
]}

Avet-Loiseau, Herve ^{[14
]}

Devlamynck, Laure ^{[15
]}

Lauwers-Cances, Valerie ^{[15
]}

Attal, Michel ^{[1
,2
]}

机构：

[1] Inst Univ Canc, Toulouse, France

[2] Univ Hosp, Toulouse, France

[3] Hop Haut Leveque, Dept Hematol, Pessac, France

[4] CHU Poitiers, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] Hop Claude Huriez, Hosp Huriez, Serv Malad Sang, Lille, France

[6] CHU Lille, Dept Hematol, Lille, France

[7] CHU Nantes, Nantes, France

[8] Ctr Hosp Univ CHU Grenoble, Dept Hematol, Grenoble, France

[9] Hop Brabois, Vandoeuvre Les Nancy, France

[10] Univ Hosp, Dept Hematol, Vandoeuvre Les Nancy, France

[11] Inst Paoli Calmettes, Marseille, France

[12] Amiens Univ Hosp, Dept Hematol, Amiens, France

[13] Univ Hosp Hotel Dieu, Clin Hematol, Nantes, France

[14] IUC T Oncopole, Unite Genom Myelome, Toulouse, France

[15] CHU Toulouse, Serv Epidemiol, USMR, Toulouse, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3159

引用

页数：4

共 36 条

[31] GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years
Mateos, Maria-Victoria
Paiva, Bruno
Cedena Romero, Maria Teresa
Puig, Noemi
Sureda Balari, Anna Maria
Oriol, Albert
Ocio, Enrique M.
Rosinol, Laura
Gonzalez-Montes, Yolanda
Jose Bargay, Juan
Gonzalez Garcia, Esther
Hernandez Garcia, Miguel Teodoro
Ramirez, Angel
Suarez-Cabrera, Alexia
Blanchard, Maria-Jesus
Garzon, Sebastian
Casado Montero, Luis Felipe
Cabanas Perianes, Valentin
Perez De Oteyza, Jaime
Gironella, Mercedes
Martinez-Lopez, Joaquin
Ana-Isabel-Teruel
Delgado, Pilar
Prieto, Elena
Lahuerta Palacios, Juan Jose
Blade, Joan
San Miguel, Jesus
BLOOD, 2023, 142
[32] MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
Korde, Neha
Mastey, Donna
Mailankody, Sham
Hassoun, Hani
Lesokhin, Alexander M.
Smith, Eric L.
Lendvai, Nikoletta
Hultcrantz, Malin
Tavitian, Elizabet
Salcedo, Meghan
Sams, Allison
Diab, Victoria
Chung, David J.
Scordo, Michael
Lahoud, Oscar B.
Landau, Heather J.
Arcila, Maria E.
Giralt, Sergio
Ho, Caleb
Roshal, Mikhail
Devlin, Sean M.
Dogan, Ahmet
Landgren, Ola
BLOOD, 2018, 132
[33] Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
Korde, Neha
Mastey, Donna
Tavitian, Elizabet
Mailankody, Sham
Lesokhin, Alexander
Hassoun, Hani
Smith, Eric L.
Lendvai, Nikoletta
Hultcrantz, Malin
Shah, Urvi
Tan, Carlyn
Lu, Sydney
Diamond, Benjamin
Salcedo, Meghan
Werner, Kelly
Chung, David J.
Scordo, Michael
Shah, Gunjan L.
Lahoud, Oscar
Landau, Heather
Arcila, Maria
Ho, Caleb
Roshal, Mikhail
Dogan, Ahmet
Derkach, Andriy
Devlin, Sean M.
Giralt, Sergio A.
Landgren, Ola
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : E193 - E196
[34] MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
Korde, Neha
Mailankody, Sham
Smith, Eric L.
Lendvai, Nikoletta
Hassoun, Hani
Lesokhin, Alexander
Hultcrantz, Malin
Chung, David J.
Shah, Gunjan L.
Koehne, Guenther
Landau, Heather
Roshal, Mikhail
Dogan, Ahmet
Giralt, Sergio A.
Mastey, Donna
Evancha, Nicole
Devlin, Sean M.
Landgren, Ola
BLOOD, 2017, 130
[35] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study
Knop, Stefan
Stuebig, Thomas
Kull, Miriam
Greil, Richard
Steiner, Normann
Bassermann, Florian
Nogai, Axel
von Lilienfeld-Toal, Marie
Janjetovic, Snjezana
Trautmann-Grill, Karolin
Bittrich, Max
Engelhardt, Monika Martha
Hoferer, Anette
Theurich, Sebastian
Binder, Mascha
Zojer, Niklas
Duerk, Heinz A.
Brueggemann, Monika
Held, Swantje
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)
Ludwig, Heinz
Sormann, Siegfried
Zojer, Niklas
Andel, Johannes
Hartmann, Bernd L.
Tinchon, Christoph
Gunsilius, Eberhard
Podar, Klaus
Egle, Alexander
Willenbacher, Wolfgang
Woll, Ewald
Ruckser, Reinhard
Bozic, Boris
Krauth, Maria-Theresa
Petzer, Andreas
Schmitt, Clemens A.
Machherndl-Spandl, Sigrid
Agis, Hermine
Paiva, Bruno
Greil, Richard
BLOOD, 2019, 134

← 1 2 3 4 →